Archives: Published Articles

Q. I am a small-scale parenteral manufacturer and have been approached to support a clinical program through Phases II and III.  What sterile manufacturing considerations are important for the small-scale production lots?

 

A. The sterile manufacturing situation always raises some interesting discussions. The statistical assurances for sterility for normal commercial lots are not available because of the usually small lots during clinical production. At the same time, the need to minimize any unanticipated clinical risks remains high. The best advice is to consult the regulations and determine what requirements you must meet to help ensure the clinical material you are manufacturing is safe. 

 

FDA Aseptic Processing Guidance

 

Sterile ManufacturingClinical trial material batches can range from as few as 200 to as many as 5000 units or more. It may not be feasible for these small-size batches to be produced on a traditional manufacturing line. In fact, some of the batches might be manufactured under a laminar flow hood by manual aseptic processing.

 

Sterility Assurance

 

It is important to remember that sterility assurance of the product must be maintained even when the clinical-trial materials are being prepared by hand because of the small lot sizes required.

 

For these small-scale batches, manufacturers need to adhere to the recommended requirements for control of the environment as defined in FDA’s aseptic processing guidance, the Parenteral Drug Association’s Technical Report #62 on manual aseptic processing, and in EudraLex Volume 4, Annex 1. In other words, the environment must be maintained and monitored with the recommendations specified in the documentation governing aseptic processing. 

 

Aseptic Pharmaceutical Manufacturing

 

Properly maintaining an aseptic pharmaceutical manufacturing environment suitable for drug products regardless of batch size is not as clear-cut as it seems. Quality personnel responsible for batch release need to take into consideration a number of factors before the lots in question can be released. These factors include assuring appropriate use of disinfectants before, during, and after manufacturing; proper gowning and aseptic technique of the operators; and making sure the environmental and qualification data support the operations.

 

So, what does this all mean? It means the company must have a robust program in place to support the sterility of the batch regardless of the lot size.

 

Sterile Pharmaceutical Manufacturing

 

There needs to be a cleaning program defining the proper use of disinfectants/sporocides before, during, and after processing. Sterile pharmaceutical manufacturing includes a gowning qualification/requalification program for personnel responsible for the product manufacturing. The gowning program should define how operators are initially qualified, how they are monitored for microbiological excursion during gowning, during manufacturing, and upon completion of manufacturing activities.

 

Aseptic Technique

 

It should also define how operators will be periodically requalified and how operators will be requalified in the event of an out-of-specification result. Operator aseptic technique should be tested through the conduction of media fills representative of the actual manufacturing runs. At a minimum, media fills should be performed annually.

 

Sterile Production

 

There also needs to be a facility maintenance program that challenges the appropriateness of the air handling system during sterile production. Establishing a periodic maintenance program for your high-efficiency particulate air (HEPA) air filtering system and performing periodic smoke studies to make sure the airflow is suitable for aseptic operations should provide quality assurance that the airflow system is in control and is functioning appropriately. 

 

In addition to the above recommendations, the company should have a program to control incoming components. Components used in the manufacture of aseptic processing on a small scale need to be rendered pyrogen free before being introduced into the manufacturing area.

 

Sterile Products

 

Small-scale batches of sterile products will not be taking advantage of continuous processes associated with large-scale lot manufacturing, so consideration must be given to how the materials and components will be introduced manually into the manufacturing area. This will require even greater emphasis on operator technique.

 

In some instances, the manufacturing equipment used in small-scale batch production is portable, so this program should also encompass the introduction of the necessary manufacturing equipment into the production area.

 

Environmental Monitoring

 

There needs to be an established environmental monitoring program. The environmental monitoring program for small-scale batch production should provide the information on the quality of the aseptic processing environment including any ancillary areas such as the equipment/component processing area, gowning rooms, laminar flow hoods, floors, ceilings, walls, and equipment surfaces including those that come into contact with the product components as well as the product itself.

 

Sterile Product Manufacturing

 

Determining the appropriate monitoring locations should be determined through a comprehensive risk evaluation. Sterile product manufacturing should periodically be reviewed and updated to reflect the most current operating conditions.

 

Finally, there needs to be consideration to final product testing and the appropriate number of product samples needed to ensure the product is sterile and safe for patients. The samples needed for testing should be taken from the beginning, middle, and end of the manufacturing run and the number taken should be reflective of the batch size.

 

Controls

 

Successfully manufacturing small-scale parenteral batches suitable for patients requires many of the same procedures and controls needed for large-scale parenteral manufacturing. If you keep in mind-regardless of batch size or manufacturing process-that the ultimate goal is to assure the sterility of the product throughout the manufacturing run and you use the data collected to determine the suitability of your processes, you should be able to produce any size batch in accordance with regulatory expectations.

 

Article Details

 

RCA

 

Pharmaceutical Technology
Vol. 41, No. 2
Pages: 82, 81

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Q: I am in the quality assurance department at my company. We are a small start-up, and one of my jobs is to develop a quality risk management plan. Can you give me some advice on what I need to consider when putting this plan together?

 

A: A well-written and well-implemented quality risk management plan is an integral and valuable element of an effective quality system. During the development and manufacturing of pharmaceutical products, the bottom line is that things can and will go wrong.

 

The purpose of a quality risk management plan is to help ensure continued compliance with regulatory requirements, such as good manufacturing practices or good laboratory practices, when events occur during manufacturing that potentially impact patient safety and product quality.

International Council for Harmonization (ICH) Q9 states,

 

“Two primary principles of quality risk management are: the evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient; and, the level of effort, formality, and documentation of the quality risk management process should be commensurate with the level of risk” (1).

 

As an RCA risk management consultant is developing your company’s plan, we consider all aspects of the operation that impact the product. Managing your company’s risk with a well-defined plan may help reduce the activities associated with poor quality and inefficiencies associated with the product and the process, such as scrap or wasted materials, customer complaints, product yield and fewer deviations.

 

Risk Evaluation

 

The best risk advisory firms will tell you to evaluate all aspects of the manufacturing process and identify areas of vulnerability. These vulnerabilities need to be evaluated during the risk assessment for impact on the operation and the potential level of risk they pose. A well-written quality risk management plan is an ongoing process requiring rigorous documentation throughout the product lifecycle.

 

It provides a solid rationale for how to improve efficiency and spend resources on the important activities to improve product quality rather than on low-risk activities that have little to no impact.

 

Risk Assessment Audits

 

The collective risk assessment team will begin the process by evaluating four basic elements that should be included in a quality risk management plan. The first element is to perform an analysis of the identified risk associated with the operations. For example, if your product is being produced using an older manufacturing line, there is a risk that the line will experience frequent breakdowns.

 

Product Quality

 

The second step is to evaluate the risk in terms of its impact on your ability to supply a quality product. In this case, frequent shut downs can lead to product rejections, yield loss, and potential drug shortages. Top risk advisory firms will identify the risk and the impact of controls to mitigate the potential situation.

 

Some of the possible mitigation control strategies might include ensuring there are appropriate change parts for the line in inventory or plans to qualify the product production on a new more modern manufacturing line.

 

Risk Management Procedure

 

The last key element needed is data input and risk management procedure design. Conducting a risk assessment audit annually with your internal team can help evaluate your data sources and when you need to employ one of your control strategies.

 

In this simple scenario, an increase in down time on the line or a steady decrease in yield could be indicators that the manufacturing line is headed for a catastrophic failure and steps need to be taken to prevent a drug shortage situation.

 

Risk Assessment

 

The above discussion is only an example of a risk assessment in one area of an operation. Other areas of the process need to be evaluated for potential vulnerabilities and risk. These areas include an evaluation of:

 

  • the raw material reliability from suppliers,
  • stability and compliance of contractual suppliers (e.g., contract manufacturing organizations, contract test organizations),
  • age and reliability of laboratory test equipment

 

In other words, a solid, well-written and dynamic quality risk management plan will evaluate the overall organization, identify high-risk vulnerabilities, identify strategies for mitigation of the high-risk vulnerabilities, and rely on data to perform continuous monitoring of the vulnerabilities. And, of course, the plan will provide the appropriate documentation and rationale for the decisions.

 

Risk Based Monitoring

 

Implementing a quality risk management plan in an organization can also be challenging. It needs to be introduced and discussed with all applicable function personnel involved in the operations including, but not limited to, finance, manufacturing, regulatory affairs, purchasing, auditing, and senior management. The plan should be dynamic and should be modified as situations change.

 

Quality System

 

Let’s say you produce a product and you have a single-source supplier for one of your excipients. You have audited the supplier and have identified some significant gaps in their quality system. You identify this vulnerability in your quality risk management plan and indicate it is a high-risk item because of the lack of compliance of the excipient vendor.

 

One of your mitigation strategies might be to qualify an alternate supplier for the excipient. Once you have qualified that alternate supplier, you need to update your plan to downgrade the risk because you have taken the appropriate steps to mitigate it and eliminate the identified vulnerability.

 

Quality Assurance

 

Quality risk management plans are important because they help improve a company’s ability to provide quality product to patients. They are contingency plans with identified actions that help to ensure a continuous supply of product to the market that meets the expectations of being safe, effective, and available. They are dynamic documents that require integration into and data inputs from all departments in order to be successfully implemented at a company.

 

 

Article Details

Pharmaceutical Technology
Volume 43, Issue 8, pgs. 49, 50

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Q: I am a quality control (QC) manager of a contract test laboratory. I am going to be upgrading the lab testing environment and would like to know if you have any advice on how I should approach this activity?
 
A: Upgrading the laboratory quality of a contract pharma manufacturer is an exciting activity. It needs to be approached with a thoughtful, well-constructed plan that does not interrupt the lab testing business needs of your clients.
 

Contract Laboratory

 

laboratory qualityYou mentioned that you are QC for the contract test laboratory quality, which would imply the products you test could include clinical trial material, final product dosage forms, and potentially, APIs. Regardless of the testing you are performing, the first step of this process should be to notify your clients of your intention to upgrade laboratory quality programs. 
 

Stability Testing

 

In addition, pharmaceutical contract manufacturing often includes performing final product release and stability testing. This is important because some clients may not wish you to perform their analyses on new equipment (e.g. API contract manufacturing). You will need to work with these clients closely to make sure you understand their concerns and that you address them before decommissioning any equipment used to analyze their materials.
 

Risk Assessment

 

The next process step for laboratory quality is to take inventory of the equipment you have. Start making some risk-based decisions on a project plan that will define what should be replaced, in what order, and what the requirements are for each. Regardless of which piece of contract labs equipment you decide to tackle first, there are several issues you must address with every replacement.
 
When contract drug manufacturing companies upgrade to a new piece of equipment to replace an aging piece (i.e., like for like), the requirements are straightforward. If you are replacing an existing technology with a significant upgrade or different technology, a more comprehensive approach will be necessary. In all cases, you will need to make sure the current equipment is performing adequately and is still capable of generating reliable results. 
 

Product Validation

 

For a simple like-for-like replacement, you should perform installation qualifications (IQ) and operational qualifications (OQ) on the new equipment.

 

The next step in the laboratory quality process would be to execute a performance qualification (PQ) and a comparison protocol. Any pharma contract manufacturing teams should be able to demonstrate the results obtained with new equipment are the same from both an efficacy and quality perspective.

 

In many cases, the PQ and comparison may be combined into one document. If the results from the protocol match up, you can decommission the old contract lab testing equipment and start using the new equipment. 

 

Manufacturing Operations

 

When changing from one laboratory quality technology to a different, more sensitive technology, there are more decisions to be considered. You need to work closely with your client on the lab testing specifics of their product so you can perform the transition with minimal disruption to their and your product flow.

 

These more complex upgrades require a lot of upfront planning. As with the like-for-like replacement, you need to make sure the current contract laboratory equipment is operating appropriately.

 

Comparison Protocol

 

As before, you need to perform the IQ and PQ on the new equipment. It is in the PQ and comparison protocol where attention to detail will be crucial to execution. For instance, when changing from high-performance liquid chromatography (HPLC) to the more sensitive ultra-high pressure liquid chromatography (UHPLC), you need to be prepared to address the possibility that you could see some unknown peaks during the analysis.

 

These contract testing peaks need to be identified and characterized before you can continue with the transfer. While this investigation is underway, you need to determine the suitability of the contract pharma product for release. This includes understanding the potential impact the peaks might have on stability of the item being analyzed.

 

Compendial Method

 

If the method being converted is a US Pharmacopeial Convention (USP) method, you need to be sure that the new methodology generates results that are equivalent or better than the results obtained using the compendial method. The comparability protocol details will help you address the unforeseen circumstances should they occur during the execution of the overall laboratory quality protocol.

 

The issues arising from the conversion of one method to a more sensitive method need to be fully addressed and explained before decommissioning the obsolete equipment.

 

Product Stability

 

There may be situations where you will need to maintain both the new and the old lab testing equipment operational at the same time. For instance, you may want to continue to monitor the stability of a product on the equipment the analysis was started on and not change to the new equipment until the last stability time point has been analyzed.

 

In this case, you will want to maintain the old equipment while utilizing the new equipment for release and future stability monitoring. These situations need to be discussed with your client and included in the laboratory timeline for transitioning the laboratory.

 

GMP Training 

 

Another important element of transitioning a contract test laboratory is making sure your analysts are properly trained on the new equipment while maintaining expertise on the old equipment until the transition is complete. Many companies selling analytical equipment have experts to perform the necessary training and to help address issues that may come up as the analysts become more familiar with the equipment.

 

It is important for the laboratory and your clients that analysts are properly trained so they can deal more effectively with problems that occur during the transition period. The more training and familiarity the analysts have in running the new equipment, the less disruption there will be to operations.

 

Clinical Labs

 

When introducing new contract laboratory equipment and new methodologies, it is important to have a comprehensive implementation plan that discusses what equipment you will introduce. The lab testing timeline for the introduction of the equipment and how you will investigate unexpected analytical results are important during the transition. Additionally, how you will make sure your analysts are appropriately trained is essential to cause minimal interruptions to operations.

 

Putting your contract laboratory plan down in writing and discussing it with your clients up front will save you a lot of time and minimize delays as you implement your plan.

 

Article Details

 

laboratory quality

 

Pharmaceutical Technology
Vol. 41, No. 6
Pages: 74-73

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Updating an Aging Facility

Manufacturing line upgrades can create uncertainty for contract manufacturing organizations (CMOs) and their pharmaceutical clients, particularly when clients assume that any facility or equipment change requires a prior approval supplement (PAS). This discussion outlines a regulatory strategy for evaluating changes based on their potential impact on approved processes, product quality, and regulatory filings, while maintaining compliance and minimizing manufacturing downtime.

 

A key starting point is a strong quality agreement that clearly defines responsibilities between the CMO and its clients. The agreement should establish who is responsible for maintaining and upgrading manufacturing facilities, while recognizing the CMO’s obligation to maintain its facility in compliance with cGMP requirements. FDA guidance on post-approval manufacturing changes also provides opportunities for certain facility and equipment modifications to be documented through an annual report rather than requiring prior approval. Examples include like-for-like replacement of equipment used in aseptic manufacturing when there is no change to the approved process or in-process control limits.

 

For changes that may generate additional client concerns, a comparability protocol can provide a structured approach to demonstrating that an upgrade will not adversely affect product quality. The protocol may also support an alternative filing strategy and allow engineering and production data to demonstrate equivalency following implementation. By combining clearly defined quality agreement responsibilities, an understanding of post-approval change requirements, and appropriate use of comparability protocols, CMOs can present clients with a documented strategy for implementing necessary facility improvements while managing regulatory risk and reducing potential downtime.

 

Read the full article: One Strategy for Updating an Aging Facility

 

The application date of May 26, 2022 for the EU In Vitro Diagnostic Medical Devices Regulation (2017/746), commonly referred to as IVDR, has come and gone.  IVDR has created challenges for in vitro diagnostic (IVD) medical device firms planning to introduce or continue to market their products to the European Union.

 

IVD Device Classifications

 

One of the biggest changes from the in vitro diagnostic directives (IVDD) to IVDR is the move from list-based IVD device classifications to a rule-based IVD medical device classification. The new classification results in four new device classes: class A (lowest risk) to class D (highest risk), where class B, C, and D would require Notified Body (NB) involvement.

 

This change requires a large number of NBs, and the increased workload is cause for concern. Moreover, it is estimated that the quantity of medical device products will increase from 20% under the Medical Devices Directive (MDD) to approximately 80% under IVDR. As of this writing, there are only four IVDR designated NBs, which highlights the shortage.

 

IVD Scheduling Delays

 

Proactive strategic planning and effective resource allocation are critical for the timely execution and implementation of a comprehensive IVDR implementation plan. IVDR manufacturers must consider and prepare for potential delays. Scheduling bottlenecks for NB conformity assessment activities can impact planned commercialization efforts for existing and/or new IVDR products. It is necessary for IVDR manufacturers to establish contingency plans to mitigate these potential challenges.

 

regulatory compliance

Additional nuances from IVDD to IVDR are based on a medical device life cycle approach and include:

 

  • Requirements for medical device manufacturers to establish and demonstrate effective quality management systems (QMS).
  • More stringent requirements for clinical evidence demonstrating conformity.
  • New requirements for postmarket performance monitoring and reporting.
  • Greater supply chain oversight and device traceability, including giving NBs discretionary authority to monitor supplier audits and subcontractor compliance.

 

IVD Timing

 

The move from IVDD to IVDR can be a time-consuming process, and many medical device companies are still in the process of making the transition.

 

Timing is an issue because companies need to:

 

  • Evaluate if their current NB is still the right partner to work with.
  • Plan the regulatory strategy of the current medical device in the field.
  • Know the IVDD certificate expiration date and prioritize the products that need immediate attention.
  • Classify devices according to the new IVDR classification rules.

 

No matter the size of your company, if you have not already started your transition, you will need to start preparing for the IVDR deadline now as it is quickly approaching. Timely compliance to IVDR requires a dedicated team of subject matter experts.

 

For example, the goal is to properly implement and execute the deliverables as laid out in your IVDR implementation plan. These deliverables may require extensive updates to a manufacturer’s existing QMS and technical documentation. Likewise, establishing or enhancing a manufacturer’s body of objective evidence of clinical performance is validation for the product lifecycle.

 

Having the Proper Team of IVD Experts

 

Organizations have a better chance of a successful transition by having a team of subject matter experts with intimate familiarity of the implementation of IVDR.

 

The subject matter experts should identify the intended purpose and inherent risks associated with your device(s). This will determine the device classification and help create technical documentation in compliance with IVDR.

 

Robust procedures for postmarket surveillance and postmarket performance follow-up must be put in place to successfully transition to IVDR.

 

Conclusion

 

If you are planning to introduce or continue to market your IVD products to any of the EU member states you must identify the new classifications your devices fall under. This includes anticipating potential scheduling delays caused by the limited number of NBs capable of reviewing IVD device classifications. Above all, plan carefully for the entire process. Putting together the right team to handle the work can ease the transition.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].